Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | MITF | O75030 | 1/20 | 0.59 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10778839 | 0.87 | SMN1; SMN2 (0.52) | NPC1RAB9AKMT2AGAATAAR1 | |
| SCHEMBL5807831 | 0.86 | ALDH1A1 (0.55) | ALDH1A1NPC1RAB9AMITFMEN1 | |
| SCHEMBL22529980 | 0.84 | PTPN1 (0.66) | ALDH1A1NPC1RAB9AMITFMEN1 | |
| Hydrochloric Acid SCHEMBL11405284 | 0.84 | SMN1; SMN2 (0.50) | NPC1RAB9AKMT2AGAATAAR1 | |
| SCHEMBL20641771 | 0.83 | P4HTM (0.59) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL21568085 | 0.82 | ALDH1A1 (0.67) | ALDH1A1NPC1RAB9AMITFTGM2 | |
| SCHEMBL3070329 | 0.82 | KMT2A (0.76) | ALDH1A1NPC1RAB9ATGM2MEN1 | |
| SCHEMBL2200065 | 0.81 | PTPN1 (0.61) | ALDH1A1NPC1RAB9AMITFTGM2 | |
| SCHEMBL5807830 | 0.80 | ALDH1A1 (0.53) | ALDH1A1NPC1RAB9AMITFTGM2 | |
| SCHEMBL2091631 | 0.80 | ALDH1A1 (0.64) | ALDH1A1NPC1RAB9AMITFTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957112-B | (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof | 渤海大学 | 2023-01-17 | — | — | CN | claimed |
| CN-114957112-A | (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof | 渤海大学 | 2022-08-30 | — | — | CN | claimed |
| WO-2019116325-A1 | TRICYCLIC COMPOUNDS AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2019-06-20 | — | — | WO | claimed |
| EP-2914614-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-16 | — | — | EP | claimed |
| CN-106046100-A | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases | 拜耳知识产权有限责任公司 | 2016-10-26 | — | — | CN | claimed |
| EP-2914614-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-09-09 | — | — | EP | claimed |
| EP-2909170-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-08-26 | — | — | EP | claimed |
| EP-2456783-B1 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ETHINYLPHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | claimed |
| US-20150218141-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | claimed |
| CN-104703970-A | Substituted carbamate compounds and their use as transient receptor potential (TRP) channel antagonists | HOFFMANN LA ROCHE | 2015-06-10 | — | — | CN | claimed |
| WO-2004002401-A2 | CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS | CYTOVIA, INC. (US) | 2004-01-08 | — | — | WO | claimed |
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | JAPAN TOBACCO, INC (JP) | 2003-10-09 | — | — | US | claimed |
| EP-1319007-A1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2003-06-18 | — | — | EP | claimed |
| US-6509352-B1 | Selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or | JAPAN TOBACCO INC. (JP) | 2003-01-21 | — | — | US | claimed |
| CN-1382119-A | Substituted alpha-hydroxy acid caspase inhibitors and uses thereof | CYTOVIA INC (US) | 2002-11-27 | — | — | CN | claimed |
| WO-2002024702-A1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| CN-1337950-A | 2-oxoquinoline compounds and medicinal uses thereof | JAPAN TOBACCO INC (JP) | 2002-02-27 | — | — | CN | claimed |
| EP-1142877-A1 | 2-OXOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2001-10-10 | — | — | EP | claimed |
| EP-0509795-A2 | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-10-21 | — | — | EP | claimed |
| US-5118678-A | Antibody inhibitors, antiinflammatory agents, fungicides, antitumor agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-06-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | CNR2, CNR1, OPRL1 | ALDH1A1 2343/4885NPC1 670/4885RAB9A 2257/4885 |
| US-20150218141-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | TRPA1, TRPV1, TRPV3 | ALDH1A1 1162/4885NPC1 704/4885RAB9A 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.